Yasser Abdelhafez

Specialist

University of California, Davis
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Introduction Our aim was to characterize the diagnostic accuracy indices for nodal (N)-staging with [ 18 F]FDG Total-Body (TB) and short-axial field-of-view (SAFOV) PET/CT in non-small cell lung cancer (NSCLC) patients referred for staging or restaging. Methods In this prospective single center cross-over head-to-head comparative study 48 patients underwent [ 18 F]FDG TB and SAFOV PET/CT on the same day. In total 700 lymph node levels (1R/L, 2R/L, 3a/p, 4R/L, 5, 6, 7, 8R/L, 9R/L, 10-14R/L) of 28 patients could be correlated to a composite reference standard (histopathological correlation, imaging after localized or systemic treatment), which allowed determination of true positive (TP), false positive (FP), true negative (TN) and false negative (FN) lesions. Lymph nodes were characterized semi-quantitatively by maximum standardized uptake value (SUV max ), tumor-to-background ratio (TBR), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) leading to threshold for each scanner. Results TB and SAFOV PET/CT showed high diagnostic accuracy indices for patient-based N-staging. Sensitivity and specificity were 86.0% (CI: 77.0–95.0%) and 98.3% (CI: 97.3–99.3%) for TB; 77.2% (CI: 66.3–88.1%) and 97.4% (CI: 96.1–98.6%) for SAFOV PET. Positive predictive value was higher for TB (81.7%, CI: 71.9–91.5%) compared to SAFOV PET (72.1%, CI: 60.9–83.4%). However, this finding was not statistically significant ( p = 0.08). Negative predictive values for TB (98.6%, CI: 97.9–99.6%) and SAFOV PET/CT (98.0%, CI: 96.9–99.1%) were comparable. Overall, NSCLC N-staging was affected in six cases on SAFOV and only in one case on TB PET/CT. Semi-quantitative analysis revealed a threshold of SUV max 3.0 to detect TP lesions on both scanners. However, TBR, MTV and TLG thresholds were lower on TB compared to SAFOV PET (TBR: 1.2 vs. 1.7, MTV: 0.5 ml vs. 1.0 ml and TLG: 1.0 ml vs. 3.0 ml). Conclusion TB and SAFOV PET/CT showed high diagnostic accuracy indices for N-staging in NSCLC patients. Sensitivity and PPV on TB PET/CT were slightly higher, compared to SAFOV PET/CT without statistical significance. However, TB PET/CT showed lower rate of incorrect N-staging and lower semi-quantitative thresholds for the detection positive mediastinal lymph nodes. Therefore, TB PET/CT might be advantageous in detecting small and low [ 18 F]FDG-avidity mediastinal lymph node metastases in NSCLC patients.

Year:

2025

Neuroimaging of blood-brain barrier permeability has been instrumental in identifying its broad involvement in neurological and systemic diseases. However, current methods evaluate the blood-brain barrier mainly as a structural barrier. Here we developed a non-invasive positron emission tomography method in humans to measure the blood-brain barrier permeability of molecular radiotracers that cross the blood-brain barrier through its molecule-specific transport mechanism. Our method uses high-temporal resolution dynamic imaging and kinetic modeling for multiparametric imaging and quantification of the blood-brain barrier permeability-surface area product of molecular radiotracers. We show, in humans, our method can resolve blood-brain barrier permeability across three radiotracers and demonstrate its utility in studying brain aging and brain-body interactions in metabolic dysfunction-associated steatotic liver inflammation. Our method opens new directions to effectively study the molecular permeability of the human blood-brain barrier in vivo using the large catalogue of available molecular positron emission tomography tracers.

Year:

2025

Year:

2025

Background Atypical lipomatous tumors (ALTs) are aggressive fat cell tumors that are distinguished from benign lipomas (SL) mainly through histopathology. Biopsy is needed for suspicious cases but can miss malignancy, so complete surgical removal and examination are essential. MRI is used but often can't differentiate ALT from SL. We introduce a machine learning method for tumor classification. Purpose To characterize the classification performance of a Bayesian additive regression trees (BART) model, built from MR radiomic features, and compare it to the readings of a musculoskeletal radiologist in classifying atypical lipomatous tumors (ALTs) from simple lipomas. Materials and Methods Retrospective data were collected from 5 medical institutions in North America, for a total of 437 patients; the mean age was 58 years ±12 years, with 248 men and 287 women. At each institution, at least T1-MRI images without contrast were collected from patients with suspected ALT prior to surgery. Histopathology was used as the reference standard. Radiomic features extracted from the MRI images were used to train the BART model and a random forest model for comparison of classification performance using a 10-fold cross-validation. Both models were compared with the classifications of an experienced (>10 years) musculoskeletal radiologist who scored the images on a 5-point scale. Results A cohort of 423 patients was included, and 1132 radiomic features were extracted from each MR study. The BART model had an accuracy, sensitivity, and specificity of 77.07% (72.76%-80.99%), 77.67% (71.36%-83.16%), and 76.50% (70.28%-81.97%), respectively, when utilizing all predictors and aggregating training and testing data from all the cohorts, approximating the human reader at 78.72% (74.51%-82.53%), 76.21% (69.80%-81.85%), and 81.11% (75.25%-86.09%), respectively. In the external validation, the average area under the curve (AUC) value across cohorts between the BART model and the human reader differed by 0.04 AUC points. From the receiver operating characteristic curve, the AUC was calculated to be 84.72% (81.00%-88.50%) and 84.74% (81.00%-88.50%) for the BART and human reader, respectively. Conclusion This study demonstrated that the BART model can distinguish ALT from lipoma with diagnostic performance comparable to an experienced human observer.

Year:

2025

Background/Objectives: Quantitative analysis of amyloid PET imaging plays a crucial role in diagnosing Alzheimer’s disease (AD), particularly in cases where visual interpretation is equivocal. Multiple commercial software tools are available for this purpose, yet differences in their quantification and diagnostic performance remain understudied, especially for Neurophet SCALE PET. Methods: We retrospectively analyzed 18F-florbetaben PET/CT scans from 129 patients with cognitive impairment, comprising 39 patients with AD and 90 with non-AD diagnoses, using three software tools: MIMneuro, CortexID Suite, and Neurophet SCALE PET. Standardized uptake value ratios (SUVRs) were obtained for six brain regions known for amyloid accumulation. Diagnostic accuracy was evaluated using ROC curve analysis, while inter-software correlations and reliability were assessed via Pearson correlation coefficients and intraclass correlation coefficients (ICC). Results: All three software programs significantly distinguished AD from non-AD patients in most brain regions. MIMneuro and Neurophet SCALE PET demonstrated the highest diagnostic performance, with MIMneuro achieving an AUC of 1.000 in the anterior cingulate gyrus. While MIMneuro and Neurophet SCALE PET showed moderate-to-strong SUVR correlations (r = 0.715–0.865), CortexID Suite showed limited correlation with the other tools. Inter-software reliability was moderate only in selected regions (ICC ≈ 0.5), indicating potential variability in SUVR measurements across platforms. Conclusions: MIMneuro, CortexID Suite, and Neurophet SCALE PET are effective for the semi-quantitative analysis of amyloid PET and can aid in the diagnosis of AD. However, clinicians should be cautious when interpreting SUVRs across different software tools due to limited inter-software consistency. Standardization efforts or consistent use of a single platform are recommended to avoid diagnostic discrepancies.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (21)

Guobao Wang

Professor

university of california davis medical center

UNITED STATES
View details

Joseph Tuscano

Professor

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details

Lorenzo Nardo

Professor

UC Davis Health System

UNITED STATES
View details

Nicolas Karakatsanis

Associate Professor of Biomedical Engineering

Weill Cornell Medical College

UNITED STATES
View details

Ramsey Badawi

Professor

university of california davis medical center

UNITED STATES
View details

Michele Guindani

Professor

University of California, Los Angeles

UNITED STATES
View details

Grigorios Panagiotou

NIHR Academic Clinical Lecturer in Endocrinology and Diabetes

University of Cambridge

UNITED KINGDOM
View details

Abhijit Chaudhari

Professor

University of California, Davis

UNITED STATES
View details

Armin Frille

-

GERMANY
View details

Negar Omidvari

Assistant Professor

University of California, Davis

UNITED STATES
View details

Lalith kumar Shiyam Sundar

W2 Professor: Digital Transformation in Radiology

Ludwig-Maximilians-Universität München

GERMANY
View details

Brahim Mehadji

Assistant Professor in Residence

University of California, Davis

UNITED STATES
View details

Moon S Chen

Professor

UC Davis Health System

UNITED STATES
View details

Valentina Medici

Professor

University of California, Davis

UNITED STATES
View details

Felipe Godinez

Assistant Professor

University of California, Davis

UNITED STATES
View details

Simon R. Cherry

Prof. of Total-Body Imaging

University of California, Davis

UNITED STATES
View details

Victoria Lyo

Associate Professor of Surgery

University of California

UNITED STATES
View details

Aaron Rosenberg

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details

Souvik Sarkar

University of California

UNITED STATES
View details

Maria Chondronikola

Principal Investigator and Lead for Human Nutrition

University of Cambridge

UNITED KINGDOM
View details

Ivo Rausch

Medical University of Vienna

AUSTRIA
View details